Mallinckrodt Inc. Announces Agreement With Xanodyne Pharmaceuticals, Inc. to Purchase Roxicodone®

Published: Aug 23, 2012

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into an agreement with Xanodyne Pharmaceuticals to purchase Roxicodone® (oxycodone hydrochloride tablets USP) in 5, 15 and 30 mg dosage strengths. Roxicodone, currently marketed in the United States, is an immediate release formulation of oxycodone indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. With this agreement, Mallinckrodt acquires all rights to the Roxicodone New Drug Application (NDA). No financial details were disclosed.

Back to news